WASHINGTON (Reuters) - The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.




Source: Supreme Court divided in battle over Teva MS drug patent


David Cottle

UBB Owner & Administrator